U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C22H24ClFO7.C5H9NO2
Molecular Weight 570.004
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of HENAGLIFLOZIN PROLINE

SMILES

OC(=O)[C@H]1CCCN1.CCOC2=CC=C(CC3=CC(=CC=C3Cl)[C@@]45OC[C@@](CO)(O4)[C@@H](O)[C@H](O)[C@H]5O)C=C2F

InChI

InChIKey=HSHUXRQZEKRWMX-CGDHVTPMSA-N
InChI=1S/C22H24ClFO7.C5H9NO2/c1-2-29-17-6-3-12(8-16(17)24)7-13-9-14(4-5-15(13)23)22-20(28)18(26)19(27)21(10-25,31-22)11-30-22;7-5(8)4-2-1-3-6-4/h3-6,8-9,18-20,25-28H,2,7,10-11H2,1H3;4,6H,1-3H2,(H,7,8)/t18-,19-,20+,21+,22+;4-/m01/s1

HIDE SMILES / InChI

Molecular Formula C22H24ClFO7
Molecular Weight 454.873
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 5 / 5
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula C5H9NO2
Molecular Weight 115.1305
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Henagliflozin (also known as SHR3824) was developed by Jiangsu HengRui Medicine as a sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus. This drug successfully passed phase I clinical trials, however, information about further development is not available.

Approval Year

PubMed

PubMed

TitleDatePubMed
SHR3824, a novel selective inhibitor of renal sodium glucose cotransporter 2, exhibits antidiabetic efficacy in rodent models.
2014 May
Evaluation of drug-drug interaction between henagliflozin, a novel sodium-glucose co-transporter 2 inhibitor, and metformin in healthy Chinese males.
2016 Aug
Pharmacokinetics and Pharmacodynamics of Henagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, in Chinese Patients with Type 2 Diabetes Mellitus.
2016 Mar

Sample Use Guides

to evaluate the pharmacodynamics (PD), pharmacokinetics (PK), safety and tolerability following single and multiple oral doses of 5mg to 20 mg SHR3824 in Type 2 diabetes mellitus patients.
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Sat Dec 16 15:33:40 GMT 2023
Edited
by admin
on Sat Dec 16 15:33:40 GMT 2023
Record UNII
4IO819SW6M
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
HENAGLIFLOZIN PROLINE
Common Name English
Henagliflozin proline [WHO-DD]
Common Name English
Code System Code Type Description
PUBCHEM
146019519
Created by admin on Sat Dec 16 15:33:40 GMT 2023 , Edited by admin on Sat Dec 16 15:33:40 GMT 2023
PRIMARY
FDA UNII
4IO819SW6M
Created by admin on Sat Dec 16 15:33:40 GMT 2023 , Edited by admin on Sat Dec 16 15:33:40 GMT 2023
PRIMARY
SMS_ID
300000040273
Created by admin on Sat Dec 16 15:33:40 GMT 2023 , Edited by admin on Sat Dec 16 15:33:40 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY